Most of us know someone who has been through breast cancer. The treatment works, the scans come back clean, and life goes on.
What the body carries forward into the years after chemotherapy is only now coming into view.
Women who received the most aggressive breast cancer chemotherapy may lose an average of 9.4 remaining years of life to faster biological aging.
That is the finding from a simulation study published in November 2026 in JAMA Network Open.
Also read: New study reveals what daily vaping may do to your lungs in just one year
Researchers at Georgetown University's Lombardi Comprehensive Cancer Center built the model. It points to cellular damage that lingers long after the last infusion.
Breast cancer survivors are the largest group inside the roughly 18.6 million cancer survivors in the United States. Many are living healthy decades after treatment.
But researchers have long suspected that chemotherapy leaves a mark that chronological age cannot capture.
How researchers reached the nine-year figure
The team adapted a long-running cancer model to track a protein called p16INK4a. It accumulates inside aged, worn-out cells and signals how much senescence has built up in the body.
Also read: How eating red meat every day may affect your heart and gut health
They ran a simulated population of US women aged 30 to 79 diagnosed between 1990 and 2030. The model was validated against data from more than 40,000 real breast cancer survivors.
Women treated with anthracycline-based regimens, the harsher group, lost a median of 7.6 more years of life than women on gentler protocols.
Risk of dying from something other than breast cancer overtook breast cancer risk 16 years earlier than chronological age would predict.
The youngest women were hit hardest. Those diagnosed between the ages of 30 and 39 lost a median of 11.7 years under the more cytotoxic treatment.
Also read: One antidepressant may be significantly better than Prozac at keeping depression from coming back
What happens in the body after chemo
The driver is a buildup of senescent cells. These are damaged cells that stop dividing but refuse to die, and they release inflammatory signals that chip away at surrounding tissue.
Lead author Swarnavo Sarkar described the mechanism in a statement from Georgetown Lombardi.
"Senescent cells secrete biological molecules that cause several aging-related diseases through added tissue damage and inflammation," he said.
The downstream risks the researchers flag include frailty, cognitive decline, and earlier onset of heart and metabolic disease.
Also read: 8 warning signs of a pinched nerve most people mistake for muscle pain
The effects do not show up right after chemo. They surface years, sometimes decades, later.
What this means for survivor care
The researchers are not telling women to skip chemotherapy. The treatment still saves lives. They argue that follow-up care should screen for aging-related conditions, not only cancer recurrence.
Physical activity shows promise as a slowing force. Welltica has reported earlier research linking regular exercise to slower aging in breast cancer survivors.
Because this is a modeling study and not a direct measurement, the exact nine-year figure is an estimate.
Also read: FDA warns shoppers after cheddar cheese recalled over Listeria risk
The pattern itself, faster biological aging after more aggressive chemotherapy, is consistent with earlier biological markers found in survivors.
The authors propose measuring biological age after treatment ends. That way, doctors could tailor follow-up to the women most at risk of accelerated aging.
Anyone with questions about their own treatment or late effects should talk with their oncologist.
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.